

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number
WO 03/032963 A2

(51) International Patent Classification⁷: A61K 31/00

(21) International Application Number: PCT/EP02/11636

(22) International Filing Date: 17 October 2002 (17.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/344495 17 October 2001 (17.10.2001) US

(71) Applicant (for all designated States except US): AVEN-
TIS PHARMA DEUTSCHLAND GMBH [DE/DE];
Brüningstrasse 50, 65929 Frankfurt (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): YUSUF, Salim
[CA/CA]; 48 Woodend Drive, Carlisle, Ontario L0R 1H2
(CA).

(74) Agent: AVENTIS PHARMA DEUTSCHLAND
GMBH; Patent- und Lizenzabteilung, Industriepark
Höchst, Geb K 801, 65926 Frankfurt (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF REDUCING TYPE 2 DIABETES IN HIGH RISK PATIENTS

(57) Abstract: The present invention relates to a method of reducing diabetes in patients who are at risk for developing diabetes comprising administering to such patients an effective amount of an angiotensin converting enzyme (ACE) inhibitor for sufficient period of time to prevent the development of diabetes in such patients; to a method of slowing or reversing the decline of B-cell function in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of B-cell function in such individual; a method of increasing islet blood flow in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual; a method of increasing pancreatic B-cell perfusion in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase pancreatic B-cell perfusion in such individual and a method of lowering aldosterone secretion and renal potassium wasting in an individual by comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to lower aldosterone secretion and renal potassium wasting in such individual. The present invention further relates to the use of an angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of B-cell function; for increasing islet blood flow; for increasing pancreatic B-cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.

WO 03/032963 A2

Method of Reducing Type 2 Diabetes in High Risk patients

FIELD OF INVENTION

The present invention relates to a method of reducing diabetes in patients who are at
5 risk for developing diabetes comprising administering to such patients an effective
amount of an angiotensin converting enzyme (ACE) inhibitor for sufficient period of
time to prevent the development of diabetes in such patients; to a method of slowing
or reversing the decline of β -cell function in an individual comprising administering to
an individual an effective amount of an angiotensin converting enzyme inhibitor for a
10 sufficient period of time to prevent the decline of β -cell function in such individual; a
method of increasing islet blood flow in an individual comprising administering to an
individual an effective amount of an angiotensin converting enzyme inhibitor for a
sufficient period of time to increase islet blood flow in such individual; a method of
increasing pancreatic β -cell perfusion in an individual comprising administering to an
15 individual an effective amount of an angiotensin converting enzyme inhibitor for a
sufficient period of time to increase pancreatic β -cell perfusion in such individual and
a method of lowering aldosterone secretion and renal potassium wasting in an
individual by comprising administering to an individual an effective amount of an
angiotensin converting enzyme inhibitor for a sufficient period of time to lower
20 aldosterone secretion and renal potassium wasting in such individual.

The present invention further relates to the use of an angiotensin converting enzyme
(ACE) inhibitor or a pharmaceutically acceptable derivative thereof in the
manufacture of a medicament for the prevention or reduction of the onset of diabetes
in patients who are at risk for developing diabetes; for the prevention, slowing or
25 reversing the decline of β -cell function; for increasing islet blood flow; for increasing
pancreatic β -cell perfusion; and for lowering aldosterone secretion and renal
potassium wasting.

BACKGROUND OF THE INVENTION

30

ACE inhibitors are well known in the art for their activity in inhibiting angiotensin
converting enzyme, thereby blocking conversion of the decapeptide angiotensin I to

CONFIRMATION COPY

angiotensin II. The principal pharmacological and clinical effects of ACE inhibitors arise from suppression of synthesis of angiotensin II. Angiotensin II is a potent pressor substance and, therefore, blood pressure lowering can result from inhibition of its biosynthesis, especially in animals and humans whose hypertension is
5 angiotensin II related. ACE inhibitors are effective antihypertensive agents in a variety of animal models and are clinically useful for the treatment of hypertension in humans. ACE inhibitors are also employed for the treatment of heart conditions such as congestive heart failure.

- 10 It has been found that ACE inhibitors are also useful for the prevention of diabetes in patients that are at high risk for developing diabetes.

The present invention relates to a method of reducing diabetes in patients who are at risk for developing diabetes comprising administering to such patients an effective
15 amount of an angiotensin converting enzyme (ACE) inhibitor for sufficient period of time to prevent the development of diabetes in such patients; to a method of slowing or reversing the decline of β -cell function in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of β -cell function in such individual; a
20 method of increasing islet blood flow in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual; a method of increasing pancreatic β -cell perfusion in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a
25 sufficient period of time to increase pancreatic β -cell perfusion in such individual and a method of lowering aldosterone secretion and renal potassium wasting in an individual by comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to lower aldosterone secretion and renal potassium wasting in such individual.

30 The present invention further relates to the use of an angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes

in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of β -cell function; for increasing islet blood flow; for increasing pancreatic β -cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.

5

Type 2 diabetes is an important and common risk factor for the development of coronary artery disease, strokes, peripheral arterial disease, and renal and eye disease. Currently, in North America, the direct and indirect costs of diabetes and its complications exceeds \$100 billion per year. This health and economic impact of diabetes is bound to increase, as the global prevalence of diabetes rises from 4.2% to 5.4% by the year 2025.

10

A growing amount of literature shows that the complications of diabetes can be reduced or prevented by improving glucose control (N. Engl. J. Med. 1993; 329:977-986; Lancet, 1998; 352:837-852), lowering blood pressure (BMJ, 1998; 317:713-720) and lipids (Lancet, 1994, 344:1383-1389), smoking cessation, and taking angiotensin converting enzyme (ACE) inhibitors (Lancet, 2000, 255; 253-259). An even more effective approach to preventing these problems would be to prevent diabetes from developing. Whereas recent evidence from trials suggests that lifestyle modifications may reduce the risk of diabetes (Diabetes Care, 1997, 20; 537-544), the long-term adherence to such interventions has not been high. Therefore alternative strategies that are more easily implemented, safe and likely to prevent not only diabetes but also its chronic consequences deserve to be investigated. Recently, it was demonstrated that the ACE inhibitor, ramipril, reduces myocardial infarction, strokes, death, and the development of diabetic nephropathy among people at high risk, both with and without a diagnosis of diabetes (Lancet, 2000, 255; 253-259; N Engl J Med. 2000; 342:145-153). It was also observed that ramipril reduced the development of diabetes in study participants without known diabetes at randomization (N Engl J Med. 2000; 342:145-153).

15

20

25

30

The phrase "diabetes" as used herein includes both type I diabetes, also known as insulin-dependent, diabetes mellitus (IDDM), and type II diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM).

The phrase "angiotensin converting enzyme inhibitor" ("ACE inhibitor") is intended to embrace an agent or compound, or a combination of two or more agents or compounds, having the ability to block, partially or completely, the rapid enzymatic
5 conversion of the physiologically inactive decapeptide form of angiotensin ("Angiotensin I") to the vasoconstrictive octapeptide form of angiotensin ("Angiotensin II").

Example of ACE inhibitors suitable for use herein are for instance the following
10 compounds: AB-103, ancovenin, benazeprilat, BRL-36378, BW-A575C, CGS-13928C, CL242817, CV-5975, Equaten, EU-4865, EU-4867, EU-5476, foroxymithine, FPL 66564, FR-900456, Hoe-065, I5B2, indolapril, ketomethylureas, KRI-1177, KRI-1230, L681176, libenzapril, MCD, MDL-27088, MDL-27467A, moveltipril, MS-41, nicotianamine, pentopril, phenacein, pivopril, rentiapril, RG-5975;
15 RG-6134, RG-6207, RGH0399, ROO-911, RS-10085-197, RS-2039, RS 5139, RS 86127, RU-44403, S-8308, SA-291, spiraprilat, SQ26900, SQ-28084, SQ-28370, SQ-28940, SQ-31440, Synecor, utibapril, WF-10129, Wy-44221, Wy-44655, Y-23785, Yissum, P-0154, zabicipril, Asahi Brewery AB-47, alatriopril, BMS 182657, Asahi Chemical C-111, Asahi Chemical C-112, Dainippon DU-1777, mixanpril,
20 Prentyl, zofenoprilat, 1-(1-carboxy-6-(4-piperidinyl) hexyl) amino)-1-oxopropyl octahydro-1H-indole-2-carboxylic acid, Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, perindoprilat and Servier S-5590, alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril,
25 trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril.

A group of ACE inhibitors of high interest are alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril,
30 trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril.

Of particular interest is the ACE inhibitor ramipril.

Pharmaceutically acceptable derivatives of ACE inhibitors are understood to include physiologically tolerable salts of ACE inhibitors, such physiologically tolerable salts are understood as meaning both their organic and inorganic salts, such as are described in Remington's Pharmaceutical Sciences (17th Edition, page 1418
5 (1985)). On account of the physical and chemical stability and the solubility, for acidic groups, inter alia, sodium, potassium, calcium and ammonium salts are preferred; for basic groups, inter alia, salts of hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, such as, for example, acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p-
10 toluenesulfonic acid are preferred.

The ACE inhibitors suitable for use herein or their pharmaceutically acceptable derivatives can be used in animals, preferably in mammals, and in particular in human, as pharmaceuticals per se, in mixtures with one another or in the form of
15 pharmaceutical preparations.

The present invention also relates to pharmaceutical formulations comprising as active ingredient at least one ACE inhibitor and/or a pharmaceutically acceptable derivative thereof in addition to customary pharmaceutically innocuous excipients
20 and auxiliaries and their use in the prevention of diabetes or the decline of β -cell function, the increasing of islet blood flow or pancreatic β -cell perfusion and lowering aldosterone secretion and renal potassium wasting and the production of medicaments therefor. The pharmaceutical preparations normally contain 0.1 to 99 percent by weight, preferably 0.5 to 95 percent by weight, of the ACE inhibitor and/or
25 an pharmaceutically acceptable derivative thereof. The pharmaceutical preparations can be prepared in a manner known per se. To this end, the ACE inhibitor and/or an pharmaceutically acceptable derivative thereof are brought, together with one or more solid or liquid pharmaceutical excipients and/or auxiliaries and, if desired, in combination with other pharmaceutical active compounds into a suitable
30 administration form or dose form, which can then be used as a pharmaceutical in human medicine or veterinary medicine.

Pharmaceuticals which contain an ACE inhibitor and/or a pharmaceutically acceptable derivative thereof can be administered orally, parenterally, intravenously,

rectally or by inhalation, the preferred administration being dependent on the particular symptoms of the disorder. The ACE inhibitors and/or an pharmaceutically acceptable derivative thereof can be used here on their own or together with pharmaceutical auxiliaries, namely both in veterinary and in human medicine.

5

The person skilled in the art is familiar on the basis of his expert knowledge with the auxiliaries, which are suitable for the desired pharmaceutical formulation. In addition to solvents, gel-forming agents, suppository bases, tablet auxiliaries and other active compound excipients, it is possible to use, for example, antioxidants, dispersants,

10

emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers or colorants.

For an oral administration form, the active compounds are mixed with the additives suitable therefor, such as excipients, stabilizers or inert diluents and are brought by means of the customary methods into the suitable administration forms, such as

15

tablets, coated tablets, hard capsules, aqueous, alcoholic or oily solutions. Inert excipients which can be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, in particular corn starch. Preparation can take place here both as dry and as moist granules. Possible oily excipients or solvents are, for example, vegetable or animal oils, such as

20

sunflower oil or codliver oil.

For subcutaneous or intravenous administration, the active compounds are brought into solution, suspension or emulsion, if desired with the substances customary therefor such as solubilizers, emulsifiers or other auxiliaries. Suitable solvents, for

25

example, are: water, physiological saline solution or alcohols, e.g. ethanol, propanol, glycerol, and additionally also sugar solutions such as glucose or mannitol solutions, or alternatively a mixture of the various solvents mentioned.

Pharmaceutical formulations suitable for administration in the form of aerosols or

30

sprays are, for example, solutions, suspensions or emulsions of the active compound of the formula I in a pharmaceutically acceptable solvent, such as, in particular, ethanol or water, or a mixture of such solvents.

If required, the formulation can also contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers, and also a propellant. Such a preparation customarily contains the active compound in a concentration from approximately 0.1 to 10, in particular from approximately 0.3 to 3, % by weight.

5

The dose of the active compound to be administered and the frequency of administration will depend on the potency and duration of action of the compounds used; additionally also on the nature of the indication and on the sex, age, weight and individual responsiveness of the mammal to be treated.

10

On average, the daily dose in a patient weighing approximately 75 kg is at least 0.001 mg/kg, preferably 0.01 mg/kg, to about 20 mg/kg, preferably 1 mg/kg, of body weight.

15 The ACE inhibitors and/or an pharmaceutically acceptable derivative thereof can also be used to achieve an advantageous therapeutic action together with other pharmacologically active compounds for the prevention of the abovementioned syndromes.

20 The following is a description of a clinical trial employing the ACE inhibitor ramipril to exemplify the methods of the present invention.

METHODS

The design of the Heart Outcomes Prevention Evaluation (HOPE) trial has been described in detail in previous publications. Briefly, individuals who were 55 years or older with no evidence of left ventricular dysfunction or heart failure and who had evidence of vascular disease or who had diabetes and one other risk factor were eligible as long as they had no indication or contraindication to receiving an ACE-inhibitor. The study was conducted in 26 hospitals in 19 countries from 1994 to 1999. All patients provided written informed consent.

Of 10576 eligible patients who participated in a run-in period during which they received 2.5 mg ramipril once daily for 1 week followed by matching placebo for 10 to 14 days, 1035 (9.8%) were excluded from randomization (3.2% for side effects, 3.7% for lack of consent). Of the remaining 9541 patients, 3654 (38.3%) had a

clinical diagnosis and 5887 (61.7%) did not at randomization. In the following it is primarily focussed on the latter group of patients. Of these patients, 5720 were randomized to receive up to 10 mg of ramipril once per day or equivalent placebo. One hundred sixty-seven patients who were randomized to receive a low dose (2.5 mg/day) of ramipril as part of the Study to Evaluate Carotid Ultrasound changes with Ramipril and Vitamin E (SECURE). Substudy results are not included. All randomized patients were also randomized to receive 400 IU of Vitamin E or placebo.

Follow-up visits occurred at 1 month and 6 months after randomization and then every 6 months (mean follow-up of 4.5 years). At each visit, it was documented whether the diagnosis of diabetes had been made since the last visit.

The primary outcome of this analysis is a new diagnosis of diabetes recorded on the basis of self-report. This diagnosis was made blinded to treatment allocation and, hence, is likely to be unbiased. Hemoglobin A_{1c} (HbA_{1c}) levels and medications used among those diagnosed as having diabetes were also recorded. The HbA_{1c} levels were determined locally. Values higher than 110% of the upper limit of normal for each laboratory were considered to be biochemical confirmation of diabetes.

Statistical analysis

Survival curves utilizing the Kaplan Meier and log-rank procedures were used to describe and compare the results in the 2 treatment groups. Because of the factorial design, all analyses were stratified for randomization to vitamin E or placebo. Subgroup analyses were conducted using tests of interaction in the Cox regression model.

RESULTS

The baseline characteristics of the patients who did not have diabetes are provided in Table 1.

Table 1. Baseline Demographics in Patients Without Diabetes Who Entered into HOPE

Characteristics	Ramipril Group	Placebo Group
Total No. randomized	2837	2883
	Mean (SD)	Mean (SD)
Age	68.3 (6.7)	65.9 (6.9)
Blood pressure, mm HG		
Systolic	136.4 (19.5)	136.7 (19.4)
Diastolic	78.2 (10.5)	78.7 (10.5)
Heart rates, beats/min	66.2 (10.8)	66.5 (10.8)
Body Mass Index	26.9 (3.9)	27.2 (4.0)
	No. (%)	No. (%)
Women	583 (20.5)	575 (19.9)
Nonwhites	233 (8.21)	239 (8.29)
Waist-hip ratio	0.93 (0.08)	0.93 (0.08)
Coronary artery disease	2645 (93.2)	2693 (93.4)
Myocardial Infarction	1784 (62.9)	1819 (63.1)
Stable, angina	1826 (64.4)	1849 (64.1)
Unstable angina	861 (30.3)	852 (29.6)
Stroke or transient ischemic stroke	347 (12.2)	318 (11.0)
Peripheral arterial disease	1106 (39.0)	1150 (39.9)
Coronary artery bypass graft surgery	871 (30.7)	881 (30.6)
Percutaneous coronary Intervention	648 (22.8)	624 (21.6)
Hypertension*	1225 (43.2)	1256 (43.6)
Cholesterol mg/dl**	1862 (65.8)	1928 (66.9)
Total >200.8		
High-density lipoprotein 34.7	472 (16.6)	533 (18.5)
Current smoking	371 (13.1)	404 (14.0)
β -Blockers	1310 (46.2)	1348 (46.8)
Lipid-lowering agents	909 (32.0)	950 (33.0)
Diuretics	363 (12.8)	356 (12.3)
Calcium-channel blockers	1376 (48.5)	1427 (49.5)
Left ventricular hypertrophy	226 (8.0)	250 (8.7)
Microalbuminuria	402 (14.2)	421 (14.6)

*History or blood pressure greater than 140/90 mm Hg.

**To convert total and high-density lipoprotein cholesterol from mg/dl to mmol/L, multiply by 0.0259]

The proportion of patients taking study ramipril or open label ACE-inhibitors in the active group was 98.3% at 2 years and 89.7% at 4 years. The proportion taking open label ACE-inhibitors in the control group was 11.6% and 27.4% respectively

New Diagnosis of Diabetes

There were 102 individuals (3.6%) in the ramipril group compared with 155 (5.4%) in the placebo group (relative risk [RR], 0.66; 95% confidence interval [CI], 0.51-0.85; $P < .001$) who reported a new diagnosis of diabetes. The proportion of patients

5 diagnosed to have diabetes and a documented glycated hemoglobin of 110% or more above the upper limit of normal (1.8% vs. 3.0%; RR, 0.60; 95% CI, 0.43-0.85; $P = .003$), those receiving an oral glucose lowering agent or insulin (2.1% vs. 3.6%; RR, 0.56; 95% CI, 0.41-0.77; $P < .001$) Those with all criteria (1.3% vs. 2.5%; RR, 0.51; 95% CI, 0.34-0.76; $P < .001$) were significantly lower in the ramipril group
10 compared with the placebo group. Vitamin E and placebo did not differ in their effect on diabetes.

Sensitivity Analysis

Because ramipril reduced the risk of cardiovascular events and diabetic
15 nephropathy, it was assessed whether the higher occurrence of these clinical events in placebo-treated patients increased the likelihood of ascertainment of diabetes in this group. Similar stratified analyses by the occurrence of other outcomes was also examined. As noted in TABLE 2 the impact of ramipril on the development of diabetes could not be explained by any confounding factor such as preferential
20 ascertainment in one group vs. the other or use of concomitant medications.

25

30

Table 2. Effect of Ramipril on the Development of Diabetes Using a Range of Criteria and Stratified by the Occurrence of Specific Events*

5

No. (%)				
Variables	Rampiril	Placebo	RR (85% CI)	P Value
New Diabetes †				
With primary event	9 (2.4)	28 (5.5)	0.48 (0.21-0.98)	.04
No primary event	93 (3.8)	129 (5.4)	0.69 (0.53-0.91)	.007
With new MA or ON	20 (5.6)	36 (8.4)	0.65 (0.38-1.12)	.12
No new MA or ON	82 (3.3)	119 (4.9)	0.67 (0.51-0.89)	.005
New Diabetes With Glycated Hemoglobin ≥ 110%, ULN‡				
With primary event	7 (1.9)	16 (3.4)	0.59 (0.24-1.43)	.23
No primary event	45 (1.8)	71 (3.0)	0.61 (0.42-0.89)	.009
With new MA or ON	10 (2.8)	25 (5.8)	0.47 (0.23-0.98)	.04
No new MA or ON	42 (1.7)	62 (2.6)	0.66 (0.48-0.98)	.04
New Diabetes With Oral Agents or Insulin §				
With primary event	5 (1.3)	16 (3.4)	0.42 (0.15-1.14)	.08
No primary event	54 (2.2)	89 (3.7)	0.58 (0.42-0.82)	.002
With new MA or ON	14 (3.9)	27 (6.3)	0.61 (0.32-1.16)	.13
No new MA or ON	45 (1.8)	78 (3.2)	0.56 (0.39-0.81)	.002
New Diabetes With Oral Agents or Insulin and Glycated Hemoglobin ≥ 110%, ULN II				
With primary event	4 (1.1)	10 (2.1)	0.54 (0.17-1.72)	.29
No primary event	32 (1.3)	61 (2.5)	0.51 (0.33-0.78)	.001
With new MA or ON	6 (1.7)	22 (5.1)	0.32 (0.13-0.79)	.009
No new MA or ON	30 (1.2)	49 (2.0)	0.60 (0.38-0.94)	.03

* RR indicates relative risk; CI, confidence interval; MA, microalbuminuria; ON, overt nephropathy; ULN, upper limits of normal; and primary event, death, myocardial infarction, or stroke.

† Controlling for primary events and development of MA or ON, new diabetes with glycated hemoglobin \geq 110 % had a 0.67 RR (95 % CI, 0.52-0.86).

‡ Controlling for primary events and development of MA or ON, new diabetes with glycated hemoglobin \geq 110 % had a 0.62 RR (95 % CI, 0.44-0.88).

§ Controlling for primary events and development of MA or ON, new diabetes with patient taking glucose-lowering therapy had a 0.58 RR (95 % CI, 0.42-0.79).

II Controlling for primary events and development of MA or ON, new diabetes with elevated glycated hemoglobin or receiving treatment had a 0.52 RR (95 % CI, 0.35-0.78).

20 Subgroup Analysis

TABLE 3 demonstrates the results among subgroups of patients with different risk factors for developing diabetes. The results are consistent among those with a waist to hip ratio below or above the median of 0.93 or less or higher than 0.93 and consistent among those with a body mass index (BMI) of 27.7 or less or higher than 27.7, those with or without a history of hypertension, those receiving or not receiving β -blockers or diuretics at randomization. A higher proportion of individuals without diabetes who were randomized to the placebo group than those randomized to the

ramipril group received diuretics or β -blockers (drugs that are associated with glucose intolerance or diabetes) during the study. However, the RR for diabetes in the subgroup of individuals who never took these drugs during the study was consistent with the overall results (RR, 0.62; 95% CI, 0.43-0.90).

5

Table 3:
Effect of Ramipril in Preventing Diabetes in Subgroups Defined at Randomization

	Ramipril			Placebo			Interaction P Value
	Patients	No.	(%)	Patients	No.	(%)	
	With Diabetes			With Diabetes			
Waist-hip ratio > 0.93	1445	63	(4.4)	1508	104	(6.9)	.46
Waist-hip ratio \leq 0.93	1392	39	(2.8)	1375	51	(3.7)	
Body mass index > 27.7 Kg/m ²	1095	63	(5.8)	1146	94	(8.2)	.79
Body mass index \leq 27.7 Kg/m ²	1742	39	(2.2)	1737	61	(3.5)	
With hypertension	1167	49	(4.2)	1192	76	(6.4)	.86
Without hypertension	1670	53	(3.2)	1691	79	(4.7)	
With microalbuminuria	402	17	(4.2)	421	35	(8.3)	.26
Without microalbuminuria	2435	85	(3.5)	2462	120	(4.9)	
Taking β -blocker	1310	52	(4.0)	1348	66	(4.9)	.15
Not taking β -blocker	1527	50	(3.3)	1535	89	(5.8)	
Taking diuretics	363	18	(5.0)	356	28	(7.9)	.86
Not taking diuretics	2474	84	(3.4)	2527	127	(5.0)	

10

Change in Weight

In 4074 patients weight was recorded at baseline and at study end. Weight increased by a mean (SD) of .98 (6.93) kg in the active group and 0.76 (8.10) kg in the control group.

15

These analyses indicate that ramipril reduced the risk of new diagnoses of diabetes among individuals with no previous history of diabetes. The magnitude of the benefit appears to be large and moreover, ACE-inhibitors also reduce macrovascular and microvascular complications of diabetes (Lancet, 2000;255;253-259). Although the data on new diagnoses of diabetes were collected prospectively in the HOPE study,

it was not a primary or secondary outcome of the trial. Therefore the results should be interpreted with caution. Nevertheless, the results are plausible given the clear statistical significance and consistency of results across subgroups, as well as using a range of approaches to diagnosing diabetes.

5

External Data

The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE) in which fasting glucose increased more with placebo (15.8 mg/dL [0.41 mmols]) than with ramipril (9.6 mg/dL [0.25 mmols]; $P = .03$) (Can. J. Cardiol. 2000;16 (suppl F) 233F). Among the patients with diabetes in the HOPE study, there was a significant reduction in HbA_{1c} levels during serial annual recordings occurred during the first 2 years (absolute difference, 0.2%) (Lancet, 2000;255;253-259). In the UK Prospective Diabetes Study (UKPDS) (BMJ 1998; 3, 17:713-720) and in the Captopril Prevention Project (Lancet, 1999 353: 611-616), patients randomized to receive ACE inhibitors had lower levels of HbA_{1c} or less development of diabetes compared with those taking β -blockers or diuretics.

However, it is not clear whether the differences in development of diabetes observed in these studies are due to a protective effect of ACE inhibitors or an adverse effect of β -blockers or diuretics.

20

Mechanisms of Action

Hypokalemia substantially impairs the insulin secretory response to glucose (J Cardiovasc Pharmacol. 1994; 24 (suppl 3) S61-S69), which may be favorably affected by ACE inhibitors. ACE inhibitors also lower aldosterone secretion and renal potassium wasting, which could preserve β -cell responsiveness. ACE inhibitors may increase islet blood flow and pancreatic β -cell perfusion by reducing angiotensin-2 mediated vasoconstriction in the pancreas (Diabetologica. 1998; 41:127-133). These effects may potentially slow or reverse the decline in β -cell function.

ACE inhibitors may reduce insulin resistance in skeletal muscles (, increase insulin-mediated glucose disposal thereby decreasing the need for pancreatic insulin secretion. The increased insulin mediated glucose uptake by skeletal muscle in response to an ACE inhibitor is due to increased bradykinin-mediated nitric oxide production and not to reductions in angiotensin 2 production or action (Am J Physiol.

1999; 277:R332-R336; Br J Clin Pharmacol 1998; 46: 467-471). Several observations suggest that agents that increase nitric oxide (such as ACE-inhibitors) may also increase insulin-mediated glucose uptake, which include that (1) both insulin-mediated vasodilation and skeletal muscle glucose metabolism are reduced in obese persons who do not have diabetes (i.e., individuals at risk for diabetes) and in individuals with type 2 diabetes, (2) inhibition of nitric oxide production reproduces this effect in lean individuals, and (3) the effect on insulin sensitivity is greater than can be accounted for by just increased skeletal muscle blood flow (Am J Cardiol. 1999, 84: 25J-27J). ACE inhibitors may also reduce insulin resistance at the liver and fat cell, which would reduced hepatic glucose production and lower free fatty acid levels (Diabetologia, 1991; 34:119-125).

Implications

The data suggesting that ramipril, an ACE inhibitor, reduces the risk of developing diabetes mellitus require confirmation because of the enormous clinical and public health potential of these findings. We are therefore embarking on a large prospective trial (Diabetes Reduction Assessment Ramipril and rosiglitazone Medication [DREAM] among individuals with impaired glucose tolerance to evaluate prospectively whether ramipril prevents diabetes.

Summary

Context: Type 2 diabetes is a growing clinical and public health problem. Preventive efforts related to lifestyle modification are not always successful; therefore, alternative prevention strategies need to be studied.

Objective: To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes among high-risk persons.

Design, Setting and Participants: The randomized, controlled Heart Outcomes Prevention Evaluation trial of 5720 patients older than 55 years without known diabetes but with vascular disease who were followed up for a mean of 4.5 years.

The study included 267 hospitals in 19 countries and was conducted between 1994 and 1999.

Intervention: Patients were randomly assigned to receive ramipril, up to 10 mg/d (n=2837), or placebo (n=2883).

Main Outcome Measure: Diagnosis of diabetes determined from self-report at follow-up visits every 6 months, compared between the 2 groups.

Results: One hundred and two individuals (3.6%) in the ramipril group developed diabetes compared with 155 (5.4%) in the placebo group (relative risk [RR], 0.66-

95% confidence interval [CI], 0.51-0.85, $P < .001$). Similar results were noted when different diagnostic criteria were used; in the ramipril group, the RR for diagnosis of diabetes and hemoglobin A_{1c} greater than 110% was 0.60 (95% CI, 0.43-0.85), for initiation of glucose-lowering therapy, 0.56 (95% CI, 0.41-0.77), and for both, 0.51 (95% CI, 0.34-0.76). These effects were also consistently seen in several subgroups examined.

Conclusions: Ramipril is associated with lower rates of new diagnosis of diabetes in high-risk individuals. Because these results have important clinical and public health implications, this hypothesis requires prospective confirmation.

The contents of all patents, patent applications, published articles, books, reference manuals and abstracts cited herein are hereby incorporated by reference in their entirety to more fully describe the state of the art to which the invention pertains.

Claims:

1. A method of reducing diabetes in patients who are at risk for developing
5 diabetes, said method comprising administering to a patient, who is at risk for developing diabetes, an effective amount of an angiotensin converting enzyme inhibitor for sufficient period of time to prevent the development of diabetes in such patients.
2. A method according to claim 1, wherein the diabetes is Type 2 Diabetes.
- 10 3. A method according to claim 1, wherein the angiotensin converting enzyme inhibitor is ramipril.
4. A method according to claim 2, wherein the angiotensin converting enzyme inhibitor is ramipril.
5. A method of slowing or reversing the decline of β -cell function in an individual
15 comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of β -cell function in such individual.
6. A method according to claim 5, wherein the angiotensin converting enzyme inhibitor is ramipril.
- 20 7. A method of increasing islet blood flow in an individual comprising:
administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual.
8. A method according to claim 7, wherein the angiotensin converting enzyme
25 inhibitor is ramipril.
9. A method of increasing pancreatic β -cell perfusion in an individual comprising:
administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase pancreatic β -cell perfusion in such individual.
- 30 10. A method according to claim 9, wherein the angiotensin converting enzyme inhibitor is ramipril.
11. A method of lowering aldosterone secretion and renal potassium wasting in an individual by comprising administering to an individual an effective amount of an

angiotensin converting enzyme inhibitor for a sufficient period of time to lower aldosterone secretion and renal potassium wasting in such individual.

12. The use of an angiotensin converting enzyme inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or
5 reduction of the onset of diabetes in patients who are at risk for developing diabetes.

13. The use according to claim 12, wherein the diabetes is Type 2 Diabetes.

14. The use according to claim 12, wherein the angiotensin converting enzyme inhibitor is ramipril.

10 15. The use according to claim 13, wherein the angiotensin converting enzyme inhibitor is ramipril.

16. The use of an angiotensin converting enzyme inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention, slowing or reversing the decline of β -cell function in an individual .

15 17. The use according to claim 16, wherein the angiotensin converting enzyme inhibitor is ramipril.

18. The use of an angiotensin converting enzyme inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for increasing islet blood flow in an individual.

20 19. The use according to claim 18, wherein the angiotensin converting enzyme inhibitor is ramipril.

20. The use of an angiotensin converting enzyme inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for increasing pancreatic β -cell perfusion in an individual.

25 21. The use according to claim 20, wherein the angiotensin converting enzyme inhibitor is ramipril.

22. The use of an angiotensin converting enzyme inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for lowering aldosterone secretion and renal potassium wasting in an individual

30 23. The use according to claim 22, wherein the angiotensin converting enzyme inhibitor is ramipril.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number
WO 03/032963 A3

(51) International Patent Classification⁷: **A61K 31/403**,
A61P 1/18, 3/10, 5/50, A61K 38/55, 31/00

(21) International Application Number: PCT/EP02/11636

(22) International Filing Date: 17 October 2002 (17.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/344495 17 October 2001 (17.10.2001) US

(71) Applicant (for all designated States except US): **AVEN-
TIS PHARMA DEUTSCHLAND GMBH** [DE/DE];
Brüningstrasse 50, 65929 Frankfurt (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **YUSUF, Salim**
[CA/CA]; 48 Woodend Drive, Carlisle, Ontario L0R 1H2
(CA).

(74) Agent: **AVENTIS PHARMA DEUTSCHLAND
GMBH**; Patent- und Lizenzabteilung, Industriepark
Höchst, Geb K 801, 65926 Frankfurt (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
24 December 2003

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **METHOD OF REDUCING TYPE 2 DIABETES IN HIGH RISK PATIENTS**

(57) Abstract: The present invention relates to the use of an angiotensin converting enzyme (ACE) inhibitor such as ramipril or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of beta-cell function; for increasing islet blood flow; for increasing pancreatic beta-cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.



WO 03/032963 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/11636

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/403 A61P1/18 A61P3/10 A61P5/50 A61K38/55
A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, EMBASE, BIOSIS, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YUSUF S ET AL: "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators." THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 20 JAN 2000, vol. 342, no. 3, 20 January 2000 (2000-01-20), pages 145-153, XP008013952 ISSN: 0028-4793 page 150, column 1, paragraph 2 table 4 --- -/--	1-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

8 October 2003

Date of mailing of the international search report

16/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Strack, E

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/EP 02/11636

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 15674 A (AVENTIS PHARMA GMBH) 8 March 2001 (2001-03-08) page 3, line 18 - line 22 page 7, line 11 - line 16 example 6 page 24, line 17 - line 18 page 27, line 19 - line 22	1-23
X	WO 01 15673 A (AVENTIS PHARMA GMBH) 8 March 2001 (2001-03-08) page 1, line 6 - line 12 page 4, line 28 claims 3,12	1-23
X	EP 0 331 014 A (THERA GES FUER PATENTE) 6 September 1989 (1989-09-06) column 1, line 1-4,23-27 claims 1,2	1-23
X	JANKA H U ET AL: "Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus." ARZNEIMITTEL-FORSCHUNG. GERMANY, WEST APR 1990, vol. 40, no. 4, April 1990 (1990-04), pages 432-435, XP001109698 ISSN: 0004-4172 abstract	1-23
X	"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators." LANCET. ENGLAND 22 JAN 2000, vol. 355, no. 9200, 22 January 2000 (2000-01-22), pages 253-259, XP002232380 ISSN: 0140-6736 abstract	1-4, 12-15
X	KRÜTZFELDT J ET AL: "Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats." NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY. GERMANY JUL 2000, vol. 362, no. 1, July 2000 (2000-07), pages 1-6, XP001148413 ISSN: 0028-1298 abstract	1

-/--

International Application No
PCT/EP 02/11636

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/EP 02/11636

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>YUSUF S ET AL: "RAMIPRIL AND THE DEVELOPMENT OF DIABETES" JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 286, no. 15, 17 October 2001 (2001-10-17), pages 1882-1885, XP008013945 ISSN: 0098-7484 abstract</p>	1-23

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/11636

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; It is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1, 2, 5, 7, 9, 11-13, 16, 18, 20 and 22 relate to a large number of possible compounds ("angiotensin converting enzyme inhibitor"). Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for ramipril, only. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Furthermore, present claims 5-11 and 16-23 relate to the treatment of diseases which are actually not well defined. The claims cover all uses relating to the terms "slowing or reversing the decline of beta-cell function" (claims 5, 6, 16 and 17), "increasing islet blood flow" (claims 7, 8, 18 and 19), "increasing pancreatic beta-cell perfusion" (claims 9, 10, 20 and 21) and "lowering aldosterone secretion and renal potassium wasting" (claims 11, 22 and 23) whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for diabetes, only.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole scope of the claims is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define uses by reference to mechanistic terms which do not allow any practical application in the form of a defined, real treatment of a pathological condition. This lack of clarity in the present case is such as to render a meaningful search over the whole scope of the claims impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear, supported and disclosed, namely the use of ramipril in relation to the treatment and prevention of diabetes.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/11636

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0115674	A	08-03-2001	AU 7649100 A	26-03-2001
			BG 106360 A	31-10-2002
			BR 0013704 A	07-05-2002
			CA 2382549 A1	08-03-2001
			CN 1368881 T	11-09-2002
			CZ 20020770 A3	12-06-2002
			EE 200200086 A	15-04-2003
			WO 0115674 A2	08-03-2001
			EP 1216038 A2	26-06-2002
			HU 0203326 A2	28-02-2003
			NO 20020978 A	18-04-2002
			SK 2692002 A3	02-07-2002
			TR 200200515 T2	21-11-2002
WO 0115673	A	08-03-2001	AU 7648400 A	26-03-2001
			BG 106319 A	29-12-2002
			BR 0013540 A	30-04-2002
			CA 2382387 A1	08-03-2001
			CN 1384756 T	11-12-2002
			CZ 20020644 A3	15-05-2002
			EE 200200085 A	15-04-2003
			WO 0115673 A2	08-03-2001
			EP 1212081 A2	12-06-2002
			HU 0202461 A2	28-12-2002
			JP 2003508426 T	04-03-2003
			NO 20020850 A	21-02-2002
			SK 2702002 A3	10-09-2002
			TR 200200518 T2	21-06-2002
			TR 200202463 T2	21-01-2003
			TR 200202464 T2	21-01-2003
			TR 200202466 T2	23-12-2002
			TR 200202467 T2	23-12-2002
			ZA 200201471 A	03-03-2003
EP 0331014	A	06-09-1989	AU 3091889 A	07-09-1989
			DK 99989 A	03-09-1989
			EP 0331014 A2	06-09-1989
			JP 1261334 A	18-10-1989
DE 4308504	A	22-09-1994	DE 4308504 A1	22-09-1994
			AU 6376694 A	11-10-1994
			WO 9421285 A1	29-09-1994

Form PCT/ISA/210 (patent family annex) (July 1992)

BEST AVAILABLE COPY